A detailed history of Gts Securities LLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Gts Securities LLC holds 15,400 shares of EDIT stock, worth $53,592. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,400
Previous 21,100 27.01%
Holding current value
$53,592
Previous $156,000 54.49%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$4.67 - $7.28 $23,817 - $37,128
-5,100 Reduced 22.86%
17,211 $80,000
Q1 2024

May 15, 2024

SELL
$7.03 - $11.07 $202,161 - $318,339
-28,757 Reduced 56.31%
22,311 $165,000
Q4 2023

Feb 14, 2024

BUY
$6.25 - $11.11 $149,843 - $266,362
23,975 Added 88.49%
51,068 $517,000
Q3 2023

Nov 15, 2023

BUY
$6.92 - $9.31 $103,232 - $138,886
14,918 Added 122.53%
27,093 $211,000
Q2 2023

Aug 15, 2023

BUY
$6.36 - $11.47 $77,433 - $139,647
12,175 New
12,175 $100 Million

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $239M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Gts Securities LLC Portfolio

Follow Gts Securities LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gts Securities LLC with notifications on news.